Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19685339 | 0.92 | POLB (0.47) | TSHRPOLBNPSR1KMT2AP2RX7 | |
| SCHEMBL21351088 | 0.89 | TSHR (0.58) | TSHRPOLBNPSR1KMT2AP2RX7 | |
| SCHEMBL19681237 | 0.89 | TSHR (0.55) | TSHRPOLBNPSR1KMT2AP2RX7 | |
| SCHEMBL19685303 | 0.89 | POLB (0.46) | TSHRPOLBNPSR1KMT2AP2RX7 | |
| SCHEMBL19681264 | 0.88 | POLB (0.44) | TSHRPOLBNPSR1F2 | |
| SCHEMBL20370185 | 0.85 | TSHR (0.52) | TSHRPOLBNPSR1KMT2AP2RX7 | |
| SCHEMBL19685305 | 0.84 | P2RX7 (0.48) | TSHRPOLBNPSR1KMT2AP2RX7 | |
| SCHEMBL21339696 | 0.83 | TSHR (0.50) | TSHRPOLBNPSR1KMT2AP2RX7 | |
| SCHEMBL18410302 | 0.83 | TSHR (0.54) | TSHRPOLBNPSR1KMT2AP2RX7 | |
| SCHEMBL19677784 | 0.83 | POLB (0.50) | TSHRPOLBNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707507-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | ADOCIA (FR) | 2023-07-25 | — | — | US | disclosed |
| US-20200306346-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20200046805-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2020-02-13 | — | — | US | disclosed |
| US-10548952-B2 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2020-02-04 | — | — | US | disclosed |
| US-10463717-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | ADOCIA (FR) | 2019-11-05 | — | — | US | disclosed |
| US-20190274953-A1 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275108-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10383918-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid | ADOCIA (FR) | 2019-08-20 | — | — | US | disclosed |
| US-10383920-B2 | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2019-08-20 | — | — | US | disclosed |
| US-20180193421-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2018-07-12 | — | — | US | disclosed |
| US-20170348394-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348423-A1 | Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348396-A1 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348395-A1 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275108-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GPR119, GLP1R | TSHR 428/4885POLB 3577/4885NPSR1 147/4885 |
| US-20180193421-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | IAPP, GPR119, GIPR | TSHR 387/4885POLB 3674/4885NPSR1 143/4885 |
| US-10463717-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | IAPP, GPR119, GIPR | TSHR 402/4885POLB 3750/4885NPSR1 116/4885 |
| US-20200306346-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, GCGR | TSHR 193/4885POLB 4208/4885NPSR1 1013/4885 |
| US-20200046805-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | TSHR 158/4885POLB 3631/4885NPSR1 205/4885 |
| US-20170348423-A1 | Injectable solution at pH 7 comprising at least one basal insulin the pl of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, IDE, INSR | TSHR 984/4885POLB 1545/4885NPSR1 3979/4885 |
| US-20170348394-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID | GCG, GLP1R, IAPP | TSHR 245/4885POLB 3283/4885NPSR1 1426/4885 |
| US-10383918-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid | GCG, GLP1R, IAPP | TSHR 245/4885POLB 3283/4885NPSR1 1426/4885 |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, IAPP | TSHR 287/4885POLB 4194/4885NPSR1 1131/4885 |
| US-20170348395-A1 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GLP1R, IAPP | TSHR 202/4885POLB 3326/4885NPSR1 997/4885 |
| US-11707507-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | IAPP, INSR, GLP1R | TSHR 158/4885POLB 3631/4885NPSR1 205/4885 |
| US-10383920-B2 | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, IDE, INSR | TSHR 1195/4885POLB 1881/4885NPSR1 3583/4885 |
| US-20170348396-A1 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, F7, GIPR | TSHR 239/4885POLB 2451/4885NPSR1 1316/4885 |
| US-20190274953-A1 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | GPR119, INSR, GCG | TSHR 605/4885POLB 1994/4885NPSR1 606/4885 |
| US-10548952-B2 | Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, F7, GIPR | TSHR 239/4885POLB 2451/4885NPSR1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.